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MicroRNAs (miRNAs) are small non-coding RNAs conserved throughout evolution whose
perceived importance for brain development and maturation is increasingly being under-
stood. Although a plethora of new discoveries have provided novel insights into miRNA-
mediated molecular mechanisms that inﬂuence brain plasticity, their relevance for neu-
ropsychiatric diseases with known deﬁcits in synaptic plasticity, such as schizophrenia
and autism, has not been adequately explored. In this review we discuss the intersection
between current and old knowledge on the role of miRNAs in brain plasticity and function
with a focus in the potential involvement of brain expressedmiRNAs in the pathophysiology
of neuropsychiatric disorders.
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INTRODUCTION
When Victor Ambros (Lee et al., 1993) and Gary Ruvkun (Wight-
man et al., 1993) ﬁrst discovered that a small non-coding RNA
lin-4was able to repress the translation of lin -14, a gene important
for developmental timing of C. elegans, the scientiﬁc community
accepted the ﬁndings as an “oddity” of worm biology. Since then
a plethora of studies have solidiﬁed the notion that these small
non-coding RNAs, which are named microRNAs (miRNAs), are
evolutionary conserved, are responsible for regulating the expres-
sion of the majority of protein coding genes, and play a critical
role in diverse cellular functions.
The biogenesis of miRNAs starts when they are transcribed
from intergenic or intronic genomic regions into primary miRNA
precursor molecules, known as pri -miRNAs (reviewed in Bar-
tel, 2004; Krol et al., 2010a). Pri -miRNAs are cleaved inside
the nucleus by the components of the microprocessor complex,
Drosha and Dgcr8, to generate hairpin structured RNA hairpins
called pre-miRNAs (Bartel, 2004; Krol et al., 2010a). Pre-miRNAs
are exported into the cytoplasm and undergo further cleavage by
RNaseIII enzyme Dicer, thereby forming a complementary duplex
of two miRNA strands (Bartel, 2004; Krol et al., 2010a). The
miRNA duplex is unwound and one of the strands, the mature
miRNA, is incorporated into a large miRNA-induced silencing
complex (miRISC), which serves to detect and bind into comple-
mentary sequences inside messenger RNAs (mRNAs). As a result
of an efﬁcient binding of the mature miRNA to its target, which is
usually in the 3′ untranslated region (3′ UTR) of the mRNA, trans-
lational inhibition and/or mRNA cleavage occur with mechanisms
that are still not fully understood (Bartel, 2004; Pillai et al., 2007;
Krol et al., 2010a). Through this miRNA-mediated control of gene
expression, miRNAs are known to not only restrict the expression
of their target genes in certain cell types or during speciﬁc devel-
opmental periods, but also to“ﬁne tune” the levels of co-expressed
targets so that a desired biological response can occur.
The mammalian brain is characterized by a notable abundance
of miRNAs. Targeted deletion studies of the miRNA processing
enzyme Dicer in different cellular populations in the mouse brain
have provided strong evidence for the signiﬁcance of miRNAs in
the development and maturation of both neuronal and glial cells,
with consequent abnormalities in brain morphology and connec-
tivity (Cuellar et al., 2008; Davis et al., 2008; Shin et al., 2009;
Dugas et al., 2010; Konopka et al., 2010; Tao et al., 2011). However,
the fact that Dicer can process other types of small non-coding
RNAs does not allow us to exclude miRNA-independent mecha-
nisms behind these observed phenotypes. In addition, deletion of
another miRNA processing enzyme Dgcr8 in neurons, results in
alterations in dendritic branching, excitatory synaptic transmis-
sion, and short term plasticity (Stark et al., 2008; Fenelon et al.,
2011; Schoﬁeld et al., 2011).
miRNAs IN BRAIN MATURATION AND FUNCTION
A large number of studies have identiﬁed miRNAs that are impor-
tant for brain development and neuronal differentiation, which
have been described in previous reviews (Li and Jin, 2010; Bian
and Sun, 2011). However the focus of this review is on miRNAs
that have been proven to inﬂuence brain maturation and plas-
ticity, mechanisms that are known to be perturbed in psychiatric
diseases (Table 1). Dendritic spines are protrusions at branches
of a neuron’s dendritic tree that form the post-synaptic end of
a synapse. Their structural properties are known to reﬂect the
degree of brain maturation and their dynamics are an important
component of brain plasticity. Moreover, alterations in dendritic
spine density have been reported in numerous neuropsychiatric
disorders, including schizophrenia and autism spectrum disor-
ders (ASD; Penzes et al., 2001). Interestingly, a loss of dendritic
spines has been reported to occur in schizophrenia (Glantz and
Lewis, 2000; Kolomeets et al., 2005; Sweet et al., 2009), whereas
an increase in the number of spines has been proposed for ASD
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Table 1 | MicroRNAs involved in brain plasticity and maturation with links to schizophrenia and autism spectrum disorders.
miRNA Validated target(s) Links to schizophrenia (or autism) Reference
miR-21 PTEN Altered expression in blood cells (altered in
cerebellum in autism)
Abu-Elneel et al. (2008), Iliopoulos et al. (2010), Meng
et al. (2006), Gardiner et al. (2011)
miR-23a Lmnb1 Altered in cerebellum and blood cells in
autism
Talebizadeh et al. (2008), Sarachana et al. (2010),
Abu-Elneel et al. (2008), Lin and Fu (2009)
miR-30a Bbnf Altered expression in PFC Perkins et al. (2007), Mellios et al. (2008)
miR-30d Bdnf Altered expression in PFC Perkins et al. (2007), Mellios et al. (2008)
miR-34a Grm7 Altered expression in PFC and blood cells Kim et al. (2010), Lai et al. (2011)
miR-128 Creb1, Src, Ppp1cc, Sp1 Altered expression in blood cells, affected by
antipsychotic treatment (altered in
cerebellum in autism)
Lin et al. (2011), Perkins et al. (2007), Abu-Elneel et al.
(2008), Gardiner et al. (2011)
miR-132 p250gap, Mecp2 Altered expression in PFC (altered in
cerebellum and blood cells in autism)
Vo et al. (2005), Wayman et al. (2008), Klein et al.
(2007), Kim et al. (2010), Miller et al. (2012),
Talebizadeh et al. (2008), Sarachana et al. (2010),
Abu-Elneel et al. (2008)
miR-134 Creb1 Altered expression in PFC and blood cells Gao et al. (2010), Santarelli et al. (2011), Gardiner et al.
(2011)
miR-137 Mb1, Lsd1, Ezh2 GWAS signiﬁcance for schizophrenia Smrt et al. (2010), Ripke et al. (2011), Sun et al. (2011),
Szulwach et al. (2010)
miR-138 Apt1 Altered expression in PFC Siegel et al. (2009), Moreau et al. (2011)
miR-181b Vsnl1, Gria2 Altered expression in PFC/STG and blood
cells (altered in blood cells in autism)
Mellios et al. (2009), Beveridge et al. (2008),
Beveridge et al. (2010), Seno et al. (2011), Gardiner
et al. (2011), Shi et al. (2012)
miR-195 Bdnf, Vsnl1, Reln, Nr3a,
HTr2a, Rgs4, Plexna2
Altered expression in PFC/STG and blood
cells, associated with changes in BDNF, SST,
and NPY (altered in blood cells in autism)
Beveridge et al. (2008), Beveridge et al. (2010), Mellios
et al. (2008), Wu et al. (2010), Sarachana et al. (2010),
Gardiner et al. (2011), Shi et al. (2012)
miR-212 Spred1, Mecp2 Altered expression in PFC (altered in
cerebellum and blood cells in autism)
Hollander et al. (2010), Im et al. (2011), Perkins et al.
(2007), Talebizadeh et al. (2008), Abu-Elneel et al.
(2008)
miR-219 CamKIIγ, Plk2 Altered expression in PFC/STG (altered in
blood cells in autism)
Beveridge et al. (2010), Kocerha et al. (2009),
Sarachana et al. (2010)
miR-346 Grid1 Altered expression in PFC and blood cells
(altered in blood cells in autism)
Zhu et al. (2009), Sarachana et al. (2010), Shi et al.
(2012)
miR-381 Bdnf Altered in cerebellum in autism Wu et al. (2010), Abu-Elneel et al. (2008)
miR-495 Bdnf Altered in blood cells in autism Wu et al. (2010), Sarachana et al. (2010)
Links to altered expression for autism are showed in parenthesis and in blue, all other descriptions refer to schizophrenia and are shown in red.
(Hutsler and Zhang, 2000). In both diseases, however, the changes
in dendritic spine density are limited to speciﬁc brain regions and
cortical layers (Glantz and Lewis, 2000; Hutsler and Zhang, 2000;
Kolomeets et al., 2005; Sweet et al., 2009).
The ﬁrst demonstration that miRNAs are localized in the
synapse and can regulate dendritic spine structure came when
miR-134 was found to be expressed in hippocampal dendritic
spines and shown to be capable of reducing spine width by target-
ing spine growth-promoting kinase Limk1 (Schratt et al., 2006).
Since then, a number of miRNAs such as miR-132 (Vo et al., 2005;
Wayman et al., 2008; Edbauer et al., 2010; Impey et al., 2010),
miR-125b (Edbauer et al., 2010), miR-138 (Siegel et al., 2009),
and miR-137 (Smrt et al., 2010) have been shown to regulate den-
dritic spine structure and morphology. In the case of miR-138
it reduces spine size by targeting depalmitoylation enzyme acyl-
protein thioesterase 1 (Apt1; Siegel et al., 2009),whereas miR-125b
reduces spine width potentially by targeting NMDA receptor 2a
(NR2a; Edbauer et al., 2010). A negative impact on spine matura-
tion was also shown for miR-137, with the proposed mechanism
of action being its effect on ubiquitin ligase Mind Bomb 1 (Mb1;
Siegel et al., 2009). Neuronal activity and cAMP response bind-
ing protein (CREB) signaling was found to regulate the expression
of miR-132, which has been shown to increase dendritic spine
density and size and promote mature spine morphology by tar-
geting spine inhibitor GTPase p250GAP (Vo et al., 2005; Wayman
et al., 2008; Impey et al., 2010). In newborn hippocampal neurons
miR-132 plays an additional role by inﬂuencing dendritic branch-
ing and synaptic integration (Magill et al., 2010; Luikart et al.,
2011). Notably, growth factors such as brain-derived neurotrophic
factor (BDNF) are known to interfere with miRNA expression
and function. For example, BDNF can induce the expression of
miR-132 and co-transcribed miR-212 (Remenyi et al., 2010) and
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inhibit the actions of miR-134 (Schratt et al., 2006), both in an
activity-dependent manner.
Despite the fact that most of the initial discoveries pertaining
to the role of miRNAs in brain maturation were based in neuronal
cultures or slices, recent studies have employed new methods for
in vivo manipulation of miRNA levels in mouse brain, and have
provided important insights into the interplay between miRNA-
mediated structural effects and their impact in brain plasticity
and function. The most well studied miRNA family is that of miR-
132/miR-212, two miRNAs of the same family that share sequence
similarities, and are expressed from the same genomic location.
BothmiR-132 andmiR-212 have been demonstrated to respond to
cocaine treatment and in vivo manipulationof miR-212 expression
was found to modulate cocaine-induced plasticity and cocaine
seeking behavior by indirectly promoting CREB signaling (Hol-
lander et al., 2010). A follow-up study revealed that miR-132/212
were involved into a complex activity-dependent loop with BDNF
and Methyl-CPG-binding protein (Mecp2), that resulted in the
observed effects in cocaine plasticity (Im et al., 2011). A similar
interplay between Mecp2 and miR-132 expression, that involves
BDNF, has been previously shown to occur in neuronal cultures
(Klein et al., 2007).
Furthermore, two independent studies have recently shown
that miR-132 is an experience-dependent miRNA in mouse visual
cortex, which regulates dendritic spine morphology in vivo, and
whose balanced expression is needed to maintain visual cortex
plasticity (Mellios et al., 2011; Tognini et al., 2011). In the ﬁrst
study miR-212 was included together with miR-132 in the sub-
set of miRNAs that showed signiﬁcant changes in their expression
following visual deprivation, an established paradigm for studying
cortical plasticity (Mellios et al., 2011). In vivo inhibition of miR-
132 function in led to increased levels of spine inhibitor p250GAP
and reduced dendritic spine density and immature morphology
(Mellios et al., 2011). In the second study,on the other hand, in vivo
upregulation of miR-132 expression promoted spine maturation
(Tognini et al., 2011). Notably, both of these manipulations abro-
gated ocular dominance plasticity, the ability of neurons of the
visual cortex to adjust their synaptic weights in response to altered
visual drive following visual deprivation during a speciﬁc sensi-
tive period of plasticity known as the critical period. These ﬁnding
suggest that balanced levels of miR-132 are required for brain plas-
ticity, and that toomuch or too littlemiR-132 expression can result
in precocious or delayed cortical maturation, respectively. The
effect of miR-132 in experience-dependent cortical maturation is
very likely tonot be limited to the visual cortex, sincemultiple stud-
ies have shown that miR-132 expression is induced in other brain
regions in an experience-dependent manner (Nudelman et al.,
2010).
Furthermore, a number of recent studies have shown that a sub-
set of brain expressed miRNAs can affect learning and memory.
Speciﬁcally, miR-134 expression in the hippocampus of Sirtuin
1 (Sirt1) knockout mice, which display memory deﬁcits during
fear conditioning and aberrant long term potentiation (LTP),
was shown to be increased, and in vivo inhibition of miR-134
expression in hippocampus, was able to rescue both the memory
and plasticity impairments (Gao et al., 2010). The novel mech-
anism proposed by this study was that SIRT1 normally inhibits
miR-134 transcription, and miR-134 targets CREB, which in turn
increases BDNF expression (Gao et al., 2010). Two more studies
described CREB-targeting miRNAs as being important for plastic-
ity andmemory,withmiR-124a shown toblock serotonin-induced
long term plasticity in Aplysia (Rajasethupathy et al., 2009), and
miR-128b proposed to regulate the formation of fear extinction
memory in mice (Lin et al., 2011). The latter study also demon-
strated that miR-128b, which is an intronic miRNA, targets its
host gene, regulator of calmodulin signaling (Src, or Rpp21), along
with a number of other plasticity-related genes such as Reelin
(Reln), protein phosphatase 1c gamma (Ppp1cc), and trans-acting
transcription factor 1 (Sp1). Of note, miR-124 is an example of
a brain enriched miRNA that acts in a temporal and cell-speciﬁc
manner, since it can also affect neuronal development (Cheng
et al., 2009),differentiation, includingneurite branching (Makeyev
et al., 2007; Visvanathan et al., 2007; Yu et al., 2008), and is able
in parallel to inﬂuence the activation of brain microglia (Pono-
marev et al., 2011), in which it is also abundantly expressed (see
also Figure 1). Finally, transgenic mice overexpressing miR-132
were also shown to have impairments in novel object recogni-
tion memory (Hansen et al., 2010). Surprisingly, the conditional
and transient deletion of Dicer1 in adult mouse forebrain caused
an unexpected improvement in learning and memory (Konopka
et al., 2010).
miRNAs IN SCHIZOPHRENIA
The ﬁrst psychiatric disease to be linked to miRNA expression
and function was Tourette’s syndrome, following the report that
mutations in the 3′UTRof SLITRK1were affecting the targeting by
miR-189 in a limited subset of patients (Abelson et al., 2005).How-
ever, a plethora of postmortem studies using subjects diagnosed
with schizophrenia provided the strongest support for aberrant
miRNAexpression inpsychiatric diseases (Perkins et al., 2007;Bev-
eridge et al., 2008, 2010; Mellios et al., 2009, 2010; Zhu et al., 2009;
Kim et al., 2010; Moreau et al., 2011; Santarelli et al., 2011; Miller
et al., 2012). Among the reported dysregulated miRNAs are those
described above as being important regulators of brainmaturation
and plasticity (Table 1). The known limitations of postmortem
studies, however, and differences in miRNA quantiﬁcation tech-
niques, have not allowed for a comprehensive description of which
miRNAs are reliably affected in schizophrenia, and more impor-
tantly which might be important for the pathogenesis of this
highly heterogeneous psychiatric disorder. In addition to indi-
vidual miRNA expression the possibility that miRNA processing
might be perturbed as a whole in a subset of subjects of schizo-
phrenia has been proposed (Beveridge et al., 2010; Santarelli et al.,
2011): although debatable, the idea deserves to be further inves-
tigated, especially in light of the fact that patients suffering from
DiGeorge 22q11,2 deletion syndrome, which harbor microdele-
tions that affect miRNA processing gene Dgcr8, display a 30-fold
increase in the prevalence of schizophrenia and schizoaffective
disorder (Lindsay et al., 1995; Murphy et al., 1999; Stark et al.,
2008).
A subset of miRNA altered in the brains of subjects diagnosed
with schizophrenia, such as miR-132/212 (Perkins et al., 2007;
Kim et al., 2010; Miller et al., 2012), miR-219 (Beveridge et al.,
2010), and miR-195 (Beveridge et al., 2008, 2010) deserves special
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attention. In the case of miR-132 and miR-212, their premen-
tioned links to activity-dependent synaptic plasticity, andneuronal
maturation, are of interest given the known abnormalities in
synaptic plasticity and connectivity observed in schizophrenia.
The fact that NMDA inhibition is reported to affect the stabil-
ity of mature miR-132 in neuronal cultures (Krol et al., 2010b) is
of additional importance since NMDA hypofunction is hypoth-
esized to be linked to the core of schizophrenia pathophysiology.
On a similar note,miR-219, whose expression is downregulated in
response to acute pharmacological blockade of NMDA receptors
with diclozapine and in NMDA receptor 1 (Nr1) knockout mice,
can target calcium/calmodulin-dependent protein kinase IIγ sub-
unit (CamKIIγ; Kocerha et al., 2009). However, both miR-219
and CamKIIγ levels are increased in the prefrontal cortex (PFC)
and superior temporal gyrus (STG) of patients with schizophrenia
(Beveridge et al., 2010), suggesting an additional level of complex-
ity. Another notable similarity between miR-219 and miR-132 is
that they were both shown to inﬂuence genes important for circa-
dian clock entrainment (Cheng et al., 2007), which is of potential
relevance to schizophrenia given the observed deﬁcits in circadian
synchronization (Lamont et al., 2010).
Another miRNA that deserves notice is miR-195 which was
found to be increased in the brain of subjects with schizophre-
nia (Beveridge et al., 2010), and which has been proven to regulate
numerous schizophrenia-related genes, such asBdnf (Mellios et al.,
2008), Reln (Beveridge et al., 2010), Visinin-like 1 (Vsnl1; Bev-
eridge et al., 2010), 5-hydroxytryptamine (serotonin) receptor 2a
(Htr2a; Beveridge et al., 2010), and glutamate receptor, ionotropic,
N -methyl-d-aspartate 3A (Grin3; Beveridge et al., 2010). The
presence of two GABAergic expressed genes (Reln, Vsnl1) in the
above list of validated miR-195 targets, and the fact that BDNF
is known to inﬂuence GABAergic gene expression and function,
position miR-195 as an intriguing candidate for schizophrenia
research given the known deﬁcits in GABAergic gene expression
and inhibitory neuron function in schizophrenia (Akbarian et al.,
1995; Guidotti et al., 2000; Costa et al., 2004; Hashimoto et al.,
2008). The ﬁndings that disease-related changes in miR-195 are
inversely correlated to those of BDNF protein levels, which in turn
are associated with the observed changes in somatostatin (Sst) and
neuropeptide Y (Npy) mRNA levels in human PFC of subjects
with schizophrenia (Mellios et al., 2009), adds value to the above
hypothesis. Last, but not least, an in silico study of schizophrenia-
relatedmiRNAs and transcription factors, depictedmiR-195 as the
core component of the predicted schizophrenia regulatory gene
networks (Guo et al., 2010).
Despite the known neuronal-speciﬁc targets of schizophrenia-
related miRNAs it is tempting to speculate that disease-related
changes in the expression of a subset of miRNAs in schizophrenia
might not be limited to neurons but could be also prevalent in
glial cell populations. For example, miR-219 expression is abun-
dantly expressed in oligodendrocytes and regulates their matu-
ration (Dugas et al., 2010), and miR-132, miR-195, and many
members of the miR-30 family are also expressed in astrocytes
(Moser and Fritzler, 2010; Mor et al., 2011; Numakawa et al., 2011;
Figure 1). In addition, theﬁndings of the existence of microvesicles
secreted by astrocytes called exosomes that contain miRNAs and
could be taken up by neurons introduce a novel unexplored mech-
anismbetween cell to cell communication in the brain (Faure et al.,
FIGURE 1 | Cell-specific expression of miRNAs regulates neuronal and
glial functions. Drawing showing examples of miRNAs enriched in different
cellular populations in the central nervous system. Aneuron is shown in
yellow–orange with miR-132 activating and miR-134, miR-137, and miR-138
inhibiting spine growth. Expression of miR-132 is present (albeit in lower
levels) in astrocytes (shown in green), which also express high levels of
miR-195 and miR-30a, miR-30b, and miR-30c. Secretion of microvesicles that
are known to contain miRNAs (exosomes) by astrocytes is also depicted.
Expression of miR-124 is shown in both neurons, where it promotes neurite
outgrowth, and microglia (shown in red), where it suppresses their activation.
Oligodendrocytes (shown in light blue) express high levels of miR-219 and
miR-23a, which regulate their differentiation.
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2006; Smalheiser, 2007; Valadi et al., 2007; Figure 1). Differen-
tial expression of miRNAs within different neuronal populations
was recently discovered in mouse neocortex, with the example
of miR-34a, a miRNA altered in the PFC of subjects diagnosed
with schizophrenia (Kim et al., 2010), being particularly enriched
in parvalbumin expressing interneurons (He et al., 2012). Future
studies using similar cell-speciﬁc methods for miRNA detection,
including exosome proﬁling, are needed to elucidate the role of
non-neuronal miRNAs in schizophrenia.
In addition to the alterations in miRNA expression in schiz-
ophrenia a growing number of genetic studies has provided
intriguing links between miRNAs and schizophrenia. Initially, sin-
gle nucleotide polymorphisms (SNPs) within miR-206 and miR-
198 were shown to be nominally associated with schizophrenia
(Hansen et al., 2007). Furthermore, another SNP in pre-miR-
30e was strongly linked to the disease (Xu et al., 2010). Notably,
the expression of miR-30e is known to be altered in the PFC
of subjects with schizophrenia, together with other members of
the miR-30 family (Perkins et al., 2007), including miR-30a and
miR-30d, which have been proven to target BDNF (Mellios et al.,
2009; Wu et al., 2010). In addition, another member of the miR-
30 family, miR-30b, was shown to be predominantly affected in
female subjects with schizophrenia, and to be inﬂuenced by a
disease-related SNP in estrogen receptor alpha (Mellios et al.,
2010). However, the most robust genetic evidence came from a
recent meta-analysis of genome-wide association studies (GWAS)
for schizophrenia that reported that a SNP within intronic miR-
137 displayed the most signiﬁcant association with the disease
(Ripke et al., 2011). This impressive ﬁnding was accompanied by
the observation that four more signiﬁcant loci contained miR-137
targets (Ripke et al., 2011).Other than the pre-mentioned reported
effect of miR-137 in dendritic spine maturation (Smrt et al., 2010),
it is of interest that Mecp2 inhibits miR-137 expression, which in
turn can target other chromatin modifying genes, such as Lysine
(K)-speciﬁc demethylase 1a (KDM1A, also known as LSD1; Sun
et al., 2011), and Histone-lysine N -methyl-transferase, Enhancer
of zeste (Drosophila) homolog 2 (EZH2; Szulwach et al., 2010).
Notably, a recent ﬁnding demonstrated that miR-137-mediated
regulation of LSD1 can also regulate neuronal differentiation and
migration by affecting neural stem cell renewal (Sun et al., 2011).
Furthermore, the interplay between miR-137 and genes important
for chromatin remodeling is of importance given the hypothesized
role of epigenetics in schizophrenia (Akbarian, 2010), and espe-
cially since a large number of other schizophrenia-relatedmiRNAs,
such as miR-132/212, miR-195 are known to be sensitive to epige-
netic regulation (Li et al., 2011; Tognini et al., 2011; Zhang et al.,
2011). Interestingly, recent work has uncovered that the deﬁcits
in miR-132 in schizophrenia are accompanied by an increase in
miR-132 target DNA methyl-transferase alpha (DNMT3a; Miller
et al., 2012), thus creating an epigenetically regulated double
negative feedback loop. Further work is warranted to determine
whether epigenetic regulation of miRNA expression could play an
important role in the pathophysiology of the disease.
miRNAs IN AUTISM SPECTRUM DISORDERS
Unlike the large number of studies examining the role of miRNAs
in schizophrenia, little is known about the potential importance
of miRNAs for ASD, and especially for the non-syndromic ASD
subtypes. So far two studies have determined the expression of
miRNAs in lymphoblastoid cell cultures of ASD patients (Abu-
Elneel et al., 2008; Talebizadeh et al., 2008; Sarachana et al., 2010;
Seno et al., 2011), and one study has identiﬁed dysregulated
miRNAs in the cerebellum of ASD patients (Abu-Elneel et al.,
2008). Among the most promising results (Table 1) is the ﬁnd-
ing of altered expression of miR-132/212, the two miRNAs of the
same family described above to be dysregulated in schizophrenia
(Perkins et al., 2007; Kim et al., 2010; Miller et al., 2012) and to be
important for the control of experience-dependent cortical plas-
ticity (Mellios et al., 2011; Tognini et al., 2011). Notably, miR-132
effects on synaptic structure are modulated by FMRP (Edbauer
et al., 2010), the product of the Fmr1 gene responsible for Fragile-
X Mental Retardation, the leading cause of mental retardation
in adults and a subtype of syndromic ASD (D’Hulst and Kooy,
2009). Intriguingly, miR-132 is known to be induced by endo-
toxins and regulate the immune response (Taganov et al., 2006;
Shaked et al., 2009; Lagos et al., 2010), as well as to be affected by
cytomegalovirus infection (Wang et al., 2008), which are known
to contribute to autism pathogenesis (Stubbs et al., 1984; Onore
et al., 2012). In addition, miR-132 levels are reduced in Rett Syn-
drome, another subtype of syndromic ASD, caused by mutations
in Mecp2 (Klein et al., 2007;Wu et al., 2010). As mentioned above,
Mecp2 can increase the expression of miR-132 through its effect
on BDNF, and decrease miR-137 by binding to its promoter and
inducing transcriptional inhibition (Klein et al., 2007; Wu et al.,
2010). However, the effect of Mecp2 on miRNAs is far more com-
plex, since Mecp2 is known to regulate a large number of miRNAs
in the mouse brain, and inﬂuence a plethora of miRNA-mediated
functions with potential importance for brain disease (Wu et al.,
2010; de Leon-Guerrero et al., 2011).
Furthermore, miR-195, miR-219, miR-346, miR-181b, and
miR-128b, all known to be altered in schizophrenia (Beveridge
et al., 2008, 2010; Zhu et al., 2009), exhibit changes inASD samples
as well (Abu-Elneel et al., 2008; Talebizadeh et al., 2008; Sarachana
et al., 2010; Seno et al., 2011), strengthening the argument for
the existence of common molecular pathways behind the patho-
physiology of both neuropsychiatric diseases. Interestingly, and
as mentioned above, miR-195 is known to target BDNF (Mellios
et al., 2009) and miR-128b to inhibit CREB (Lin et al., 2011),
whereas miR-132/212 are induced by BDNF and positively regu-
late CREB signaling (Hollander et al., 2010; Remenyi et al., 2010),
which, in conjunction with two more BDNF regulating miRNAs
(miR-495,miR-381;Wu et al., 2010) altered in autism (Talebizadeh
et al., 2008; Sarachana et al., 2010), allows us to speculate that
activity-dependentmiRNAs could be affected inASD. Such abnor-
malities in activity-dependent BDNF/CREB-related miRNAs are
expected to have an impact on synaptic connectivity and matura-
tion, which are known to be perturbed in ASD. As in the case
of schizophrenia, the cell-speciﬁcity of ASD-related alterations
in miRNA expression warrants further investigation, since dif-
ferentially expressed miRNAs are known to be also expressed in
astrocytes and oligodendrocytes (Dugas et al., 2010; Moser and
Fritzler, 2010; Numakawa et al., 2011; Mor et al., 2011; Lin and
Fu, 2009. In the case of miR-23a, for example, which together with
miR-132 is altered in three out of four ASD studies (Abu-Elneel
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et al., 2008; Talebizadeh et al., 2008; Sarachana et al., 2010), there is
strong evidence suggesting that it is an oligodendrocyte enriched
miRNA that regulates their maturation by inhibiting lamin B1
(Lin and Fu, 2009; see also Figure 1). Another pathway that is
emerging to be regulated by ASD altered miRNAs and that is also
affected by BDNF signaling, is that of phosphoinositide 3-kinase
(PI3K)/protein kinase B (PKB also known as Akt), with the best
example being the reported changes in miR-21, a miRNA known
to target phosphatase and tensin homolog (PTEN; Meng et al.,
2006; Iliopoulos et al., 2010), which is responsible for inactivating
Akt. Given that patients with PTEN mutations represent a sub-
stantial proportion of syndromic ASD (Varga et al., 2009), further
research is warranted to elucidate the importance of miR-21 for
ASD pathogenesis.
CONCLUSION
The increasing number of studies uncovering novel miRNA-
mediated mechanisms that inﬂuence brain maturation and plas-
ticity, in conjunction with the parallel ﬁndings for the potential
involvement of such miRNAs in schizophrenia and autism, ele-
vates the importance of miRNAs for brain function and dysfunc-
tion to a new level. It is tempting to speculate that a subset of
the reported dysregulated in neuropsychiatric disorders miRNAs
might turn out to be integral for shedding light on the elusive
pathophysiology or pathogenesis of these complex and enigmatic
disorders. Moreover, given the fact that both autism and schiz-
ophrenia pathogenesis appears to be inﬂuenced by mechanisms
related to neurodevelopment, priority should be given to ASD
or schizophrenia altered miRNAs with speciﬁc developmental
patterns. For example, the experience-dependent miR-132/212
miRNA family holds great promise for schizophrenia, since its
expression in mouse PFC peaks around adolescence (Miller et al.,
2012), which coincides with the age of onset of schizophrenia. In
theory, if a miRNA is indeed regulating genes and pathways that
could trigger the onset of the disease, it is expected that its dys-
regulation will have the biggest impact at the time point when
its expression reaches the maximum, because this is when its tar-
gets will be most robustly affected. Moreover, in the case where
alterations in speciﬁc miRNAs are only an epiphenomenon of
the disease, they could be ideal biomarker candidates, given the
increased stability and durability of miRNAs, even in harsh han-
dling conditions (Chen et al., 2008). Indeed, recent studies are
exploring this possibility and have already reported some aber-
rantly expressed miRNAs in blood cells that could be associated
with schizophrenia symptomatology, includingmiRNAs known to
be altered in the brains of schizophrenia subjects aswell, or affected
by antipsychotic treatment (Gardiner et al., 2011; Lai et al., 2011;
Woelk et al., 2011; Shi et al., 2012; Table 1). Ideally, the use of blood
expressed miRNAs as biomarkers can be expanded to monitor the
progress and response to therapeutic treatment of a disease, such
as in the case of miR-134 and bipolar disorder (Rong et al., 2011).
Lastly, the emerging technologies of induced neurons (Ambasud-
han et al., 2011),or induced pluripotent stem cell-derived (Pedrosa
et al., 2011) neurons, from patient ﬁbroblasts might be an alter-
native for uncovering novel miRNA biomarkers, as well as for
discovering new treatment options.
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